US 11,851,432 B2
Triazolopyrimidine compounds and their use in treating cancer
Frederick Woolf Goldberg, Cambridge (GB); Attilla Kuan Tsuei Ting, Cambridge (GB); Gillian McGregor Lamont, Cambridge (GB); David Buttar, Cambridge (GB); and Jason Grant Kettle, Cambridge (GB)
Assigned to Dizal (Jiangsu) Pharmaceutical Co., Ltd., Wuxi (CN)
Filed by Dizal (Jiangsu) Pharmaceutical Co., Ltd., Wuxi (CN)
Filed on Jul. 5, 2021, as Appl. No. 17/367,450.
Application 17/367,450 is a division of application No. 17/095,729, filed on Nov. 11, 2020, granted, now 11,084,827.
Application 17/095,729 is a continuation of application No. PCT/EP2019/062020, filed on May 10, 2019.
Claims priority of provisional application 62/670,075, filed on May 11, 2018.
Prior Publication US 2021/0340150 A1, Nov. 4, 2021
Int. Cl. C07D 487/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A method for treating cancer in warm-blooded animal in need of such treatment, which comprises administering to the warm-blooded animal a therapeutically effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 and R2 each independently represent hydrogen or methyl;
X represents CH2 or O;
Ring A and Ring B each independently represent a ring selected from phenyl, pyridinyl, pyrazinyl, pyrimidinyl and pyridazinyl, wherein each of Ring A and Ring B are independently optionally substituted with one or more substituents selected from C1-3 alkyl and C1-3 alkoxy;
Ring C represents a 5 to 9 membered monocyclic or bicyclic saturated heterocycloalkyl optionally containing one or more additional heteroatoms independently selected from O, N and S, wherein Ring C is optionally substituted with one or more substituents selected from C1-3 alkyl, optionally substituted with methoxy or hydroxyl; dioxo, C0-2 alkyl-C(O)N(Me)2, C(O)C1-2 alkyl and S(O)2C1-2 alkyl.